20.51 +0.00 (0.00%)
TRGT
Stock Details
Last Trade:20.51 Change:+0.00 (0.00%) Prev Close:20.51 Open: 20.42 Days Range:20.38 – 20.86 52 Week Range: 2.00 - 24.50 Volume:143250 P/E: N/AEPS:-0.75
View AllRecent Alerts 02/10/10
Recent Alert on 01/11/10 at 9:01am
Targacept (TRGT) Agreement With AstraZeneca Becomes Effective, Triggering $200M Upfront Payment
Targacept (TRGT) Agreement With AstraZeneca Becomes Effective, Triggering $200M Upfront Payment
Targacept, Inc. (Nasdaq: TRGT) said its collaboration and license agreement with AstraZeneca (NYSE: AZN) for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early... Read More
Recent Alert on 01/11/10 at 9:01am
Targacept (TRGT) Agreement With AstraZeneca Becomes Effective, Triggering $200M Upfront Payment
Targacept (TRGT) Agreement With AstraZeneca Becomes Effective, Triggering $200M Upfront Payment
Recent Alert on 12/03/09 at 10:38am
Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
Recent Alert on 12/03/09 at 6:55am
AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
Recent Alert on 12/03/09 at 6:55am
AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
View AllRecent Press Releases
Press Release on 02/08/10 at 8:55am
Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease
Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease
View AllRecent SEC Filings
No Recent SEC Filings Available